{ "schemaVersion": 1, "organisationId": "O-fb1a3f60834d427eb31108d33647c9a1", "slug": "elanco-animal-health-inc", "name": "Elanco Animal Health Inc", "updatedAt": "2026-10-02T13:00:13.179587Z", "sections": [ { "type": "OVERVIEW", "text": "Elanco Animal Health Inc. is a global animal-health company that develops, manufactures, markets and sells products to prevent and treat disease in companion and farm animals. Its offerings include pet-health products such as parasiticides, vaccines and therapeutics, and farm-animal products focused on disease prevention and treatment, animal performance and food safety. [P900108][T8913335][T3339922] Elanco states its purpose as “making life better for animals makes life better.” [P900108]\n\nThe company’s products are sold in more than 90 countries. [P900108] Elanco reported $4.715 billion in revenue for 2025 and describes a global team of more than 9,000 members across 40+ countries. [T10755470][https://www.elanco.com/us/newsroom/featured-articles/great-places-to-work-certification]\n[P900108][T8913335][T3339922][T10755470][https://www.elanco.com/us/newsroom/featured-articles/great-places-to-work-certification]", "updatedAt": "2026-10-02T13:00:13.179587Z" }, { "type": "PRODUCTS", "text": "Elanco’s pet-health products include parasiticides, dermatology treatments, vaccines and pain therapeutics. Advantage Family products and Seresto provide flea and tick prevention; Seresto is a slow-release collar with protection lasting up to eight months. The Credelio Family targets fleas and ticks, while Credelio Quattro is a monthly chew for dogs that also protects against heartworm and several worms. Other examples include Zenrelia, a once-daily oral treatment for canine pruritus and atopic dermatitis; Tru vaccines; and Galliprant for osteoarthritis pain and inflammation in dogs. [P33152642][P9265790]\n\nFarm-animal products include feed additives, vaccines, injectables, insecticides and enzymes. AviPro poultry vaccines address diseases including Newcastle disease, infectious bronchitis and Salmonella; Experior is used to reduce ammonia emissions from cattle or their waste. Maxiban and Monteban feed additives help prevent coccidiosis in broiler chickens, while Rumensin supports cattle feed efficiency, milk production and weight gain and helps prevent or control coccidiosis. Other named products include Baytril and Pulmotil antibiotics, Denagard for swine dysentery and the Hemicell feed enzyme. [P95517216][P65118019]\n\nElanco’s 2026 portfolio addition through its AHV International acquisition includes animal-welfare and productivity products aimed particularly at cattle, such as StopLac, used to reduce milk production during dry-off, and plant-derived Quorum Sensing Technology, intended to disrupt biofilm formation. [P146465990][P146466123][https://www.elanco.com/us/newsroom/featured-articles/elanco-acquires-ahv-international] Elanco also offers customer support and dairy tools including UpLook; services are not separately quantified in the cited revenue disclosures. [https://farmanimal.elanco.com/us/dairy]\n\nFor 2025, Pet Health accounted for 49% of revenue, Farm Animal 50%, and Contract Manufacturing and Other 1%. The five largest product families—Advantage Family, Seresto, Credelio Family, Rumensin and Maxiban/Monteban—together contributed about 38% of revenue; Advantage Family alone contributed about 10%. [P112433154][T2706537] For the six months ended June 30, 2026, Pet Health represented approximately 52.1% of revenue, Farm Animal 46.5%, and Contract Manufacturing and Other 1.3%. [T16763397]\n[P33152642][P9265790][P95517216][P65118019][P146465990][P146466123][https://www.elanco.com/us/newsroom/featured-articles/elanco-acquires-ahv-international][https://farmanimal.elanco.com/us/dairy][P112433154][T2706537][T16763397][https://www.elanco.com/us/newsroom/featured-articles/elanco-acquires-ahv-international][https://farmanimal.elanco.com/us/dairy]", "updatedAt": "2026-10-02T13:00:13.179587Z" }, { "type": "GEOGRAPHY", "text": "In FY2025, Elanco reported $2.234 billion in U.S. revenue and $2.481 billion in international revenue—approximately 47.4% and 52.6% of its $4.715 billion total, respectively. The filing presents geographic sales as United States and International, rather than breaking them down by individual country. [T5924114] [P863051]\n\nElanco’s global headquarters is in Indianapolis, Indiana; the company has said its new headquarters serves more than 725 Indianapolis-area employees. [P6781386] [https://www.elanco.com/us/newsroom/featured-articles/elanco-animal-health-opens-new-global-headquarters] The FY2025 filing lists 16 manufacturing sites across nine countries: the United States, Brazil, China, France, Germany, Mexico, South Korea, Taiwan and the United Kingdom. [P37752147] [T2792285] Clinton, Indiana, is identified as the largest manufacturing site. [P106898233]\n\nAs of December 31, 2025, Elanco had more than 1,000 employees in global R&D and Regulatory Affairs. Its listed R&D locations include sites in Australia, Brazil, China, Germany, India, Switzerland, the United Kingdom and the United States, with Indianapolis serving as R&D headquarters. [P46279783] [P111898586] Elanco’s website says its products and services reach more than 90 countries and lists 9,000 team members worldwide; it does not provide a country-by-country employee distribution in those figures. [https://www.elanco.com/en-ca/about-us/our-locations] [https://www.elanco.com/us/about-us]\n[T5924114][T5924114][T5924114][P863051][P6781386][https://www.elanco.com/us/newsroom/featured-articles/elanco-animal-health-opens-new-global-headquarters][P37752147][T2792285][T2792285][T2792285][T2792285][T2792285][T2792285][T2792285][T2792285][T2792285][T2792285][T2792285][P106898233][P46279783][P111898586][https://www.elanco.com/en-ca/about-us/our-locations][https://www.elanco.com/us/about-us][https://www.elanco.com/us/newsroom/featured-articles/elanco-animal-health-opens-new-global-headquarters][https://www.elanco.com/en-ca/about-us/our-locations][https://www.elanco.com/us/about-us]", "updatedAt": "2026-10-02T13:00:13.179587Z" }, { "type": "SEGMENTS", "text": "Elanco Animal Health reports one business segment, encompassing development, manufacturing, marketing and sales of animal-health products for both pets and farm animals. The company evaluates and manages the business on a consolidated, global basis rather than reporting separate operating segments by product category or geography. [P55563375] [T3544832]\n\nFor FY2025, the single segment generated $4.715 billion in revenue, equal to approximately 100% of consolidated revenue. Elanco does not separately report revenue contributions for Pet Health versus Farm Animal products in its segment disclosure. [T1497855] [T8913335]\n\nThe product areas described within the business are not separate reportable segments. Pet Health includes parasiticides, dermatology, vaccines, and pain and other therapeutics. Farm Animal products serve cattle, poultry, swine, and sheep, with offerings directed at animal performance, disease prevention and treatment, food safety, and sustainability; product types include medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes. [P55563375] [T3339922]\n[P55563375][T3544832][T1497855][T8913335][T3339922]", "updatedAt": "2026-10-02T13:00:13.179587Z" }, { "type": "HISTORY", "text": "Elanco’s roots trace to Eli Lilly’s animal-health work, beginning in 1892. Lilly launched an antibiotic developed exclusively for veterinary use in 1953, organized its agricultural and animal-science activities into a division in 1954, and adopted the Elanco name in 1960. [https://www.elanco.com/en-gb/about-us/our-history] [https://www.elanco.com/en-gb/about-us/our-journey]\n\nElanco expanded through acquisitions, including Janssen Animal Health in 2011, Lohmann Animal Health in 2014, and Novartis Animal Health in 2015. [https://www.elanco.com/en-gb/about-us/our-journey] In 2018, it became a publicly traded company through an initial public offering; Lilly completed Elanco’s full separation in March 2019. Elanco also acquired Aratana Therapeutics in 2019, broadening its companion-animal portfolio. [https://investor.elanco.com/static-files/19ef7e5a-185c-4589-a101-5ec62059f513]\n\nIn 2020, Elanco completed its acquisition of Bayer Animal Health, a major expansion of its animal-health business. [https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-bayer-animal-health] It acquired Kindred Biosciences in 2021, adding therapeutic development assets. [https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-kindred-biosciences] In 2024, it sold its aqua business to Merck Animal Health. [https://www.elanco.com/us/newsroom/press-releases/elanco-completes-sale-of-aqua-business] In April 2026, Elanco acquired Dutch farm-animal-health company AHV International and selected affiliate assets. [P146465990]\n[https://www.elanco.com/en-gb/about-us/our-history][https://www.elanco.com/en-gb/about-us/our-journey][https://investor.elanco.com/static-files/19ef7e5a-185c-4589-a101-5ec62059f513][https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-bayer-animal-health][https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-kindred-biosciences][https://www.elanco.com/us/newsroom/press-releases/elanco-completes-sale-of-aqua-business][P146465990][https://www.elanco.com/en-gb/about-us/our-history][https://www.elanco.com/en-gb/about-us/our-journey][https://investor.elanco.com/static-files/19ef7e5a-185c-4589-a101-5ec62059f513][https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-bayer-animal-health][https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-kindred-biosciences][https://www.elanco.com/us/newsroom/press-releases/elanco-completes-sale-of-aqua-business]", "updatedAt": "2026-10-02T13:00:13.179587Z" } ], "sources": [ { "id": "P900108", "href": "https://app.finbar.com/go?id=P900108", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T8913335", "href": "https://app.finbar.com/go?id=T8913335", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T3339922", "href": "https://app.finbar.com/go?id=T3339922", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T10755470", "href": "https://app.finbar.com/go?id=T10755470", "label": "Elanco Animal Health Inc — Press release (2025 Y)", "documentId": "D-c655089bba7a41099055ec366c6ea215" }, { "id": "https://www.elanco.com/us/newsroom/featured-articles/great-places-to-work-certification", "href": "https://www.elanco.com/us/newsroom/featured-articles/great-places-to-work-certification", "label": "www.elanco.com" }, { "id": "P33152642", "href": "https://app.finbar.com/go?id=P33152642", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P9265790", "href": "https://app.finbar.com/go?id=P9265790", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P95517216", "href": "https://app.finbar.com/go?id=P95517216", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P65118019", "href": "https://app.finbar.com/go?id=P65118019", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P146465990", "href": "https://app.finbar.com/go?id=P146465990", "label": "Elanco Animal Health Inc — Full financial report (2026 Q 2)", "documentId": "D-38f6b28021014b27b337613d936a3971" }, { "id": "P146466123", "href": "https://app.finbar.com/go?id=P146466123", "label": "Elanco Animal Health Inc — Full financial report (2026 Q 2)", "documentId": "D-38f6b28021014b27b337613d936a3971" }, { "id": "https://www.elanco.com/us/newsroom/featured-articles/elanco-acquires-ahv-international", "href": "https://www.elanco.com/us/newsroom/featured-articles/elanco-acquires-ahv-international", "label": "www.elanco.com" }, { "id": "https://farmanimal.elanco.com/us/dairy", "href": "https://farmanimal.elanco.com/us/dairy", "label": "farmanimal.elanco.com" }, { "id": "P112433154", "href": "https://app.finbar.com/go?id=P112433154", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T2706537", "href": "https://app.finbar.com/go?id=T2706537", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T16763397", "href": "https://app.finbar.com/go?id=T16763397", "label": "Elanco Animal Health Inc — Full financial report (2026 Q 2)", "documentId": "D-38f6b28021014b27b337613d936a3971" }, { "id": "T5924114", "href": "https://app.finbar.com/go?id=T5924114", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P863051", "href": "https://app.finbar.com/go?id=P863051", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P6781386", "href": "https://app.finbar.com/go?id=P6781386", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "https://www.elanco.com/us/newsroom/featured-articles/elanco-animal-health-opens-new-global-headquarters", "href": "https://www.elanco.com/us/newsroom/featured-articles/elanco-animal-health-opens-new-global-headquarters", "label": "www.elanco.com" }, { "id": "P37752147", "href": "https://app.finbar.com/go?id=P37752147", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T2792285", "href": "https://app.finbar.com/go?id=T2792285", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P106898233", "href": "https://app.finbar.com/go?id=P106898233", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P46279783", "href": "https://app.finbar.com/go?id=P46279783", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "P111898586", "href": "https://app.finbar.com/go?id=P111898586", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "https://www.elanco.com/en-ca/about-us/our-locations", "href": "https://www.elanco.com/en-ca/about-us/our-locations", "label": "www.elanco.com" }, { "id": "https://www.elanco.com/us/about-us", "href": "https://www.elanco.com/us/about-us", "label": "www.elanco.com" }, { "id": "P55563375", "href": "https://app.finbar.com/go?id=P55563375", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T3544832", "href": "https://app.finbar.com/go?id=T3544832", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "T1497855", "href": "https://app.finbar.com/go?id=T1497855", "label": "Elanco Animal Health Inc — Full financial report (2025 Y)", "documentId": "D-339ff6136ce94595a1f949623fe92482" }, { "id": "https://www.elanco.com/en-gb/about-us/our-history", "href": "https://www.elanco.com/en-gb/about-us/our-history", "label": "www.elanco.com" }, { "id": "https://www.elanco.com/en-gb/about-us/our-journey", "href": "https://www.elanco.com/en-gb/about-us/our-journey", "label": "www.elanco.com" }, { "id": "https://investor.elanco.com/static-files/19ef7e5a-185c-4589-a101-5ec62059f513", "href": "https://investor.elanco.com/static-files/19ef7e5a-185c-4589-a101-5ec62059f513", "label": "investor.elanco.com" }, { "id": "https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-bayer-animal-health", "href": "https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-bayer-animal-health", "label": "www.elanco.com" }, { "id": "https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-kindred-biosciences", "href": "https://www.elanco.com/us/newsroom/press-releases/elanco-closes-acquisition-of-kindred-biosciences", "label": "www.elanco.com" }, { "id": "https://www.elanco.com/us/newsroom/press-releases/elanco-completes-sale-of-aqua-business", "href": "https://www.elanco.com/us/newsroom/press-releases/elanco-completes-sale-of-aqua-business", "label": "www.elanco.com" } ] }